No worries, I used all the money from shorting AZEK from $39.50 down to $29
Another 20%+ savant call.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: THE GREEN MARKET
- Thread starter stonedinvestor
- Start date
No worries, I used all the money from shorting AZEK from $39.50 down to $29
Another 20%+ savant call.
Ok this is one of the funniest things I have ever seen. Van if we do one of these it will be MUCHO DIFFERENT with the girls involved I want to really Howard Stern this up.. and of course live air consumption.
$8 or $9 to $27 the fathead says, steak juice drool and all,,,,. it did that in one day i am a holder.....
Well of course $4 today. These two should be locked up.
$8 or $9 to $27 the fathead says, steak juice drool and all,,,,. it did that in one day i am a holder.....
Well of course $4 today. These two should be locked up.
I think I bought those same sunglasses in a pinch the other day at Dollar General.Ok this is one of the funniest things I have ever seen. Van if we do one of these it will be MUCHO DIFFERENT with the girls involved I want to really Howard Stern this up.. and of course live air consumption.
$8 or $9 to $27 the fathead says, steak juice drool and all,,,,. it did that in one day i am a holder.....
Well of course $4 today. These two should be locked up.
I know you chose this particular airline because I used to be long. That was a ways ago- we made a bundle.
Matterport appoints Tom Klein as CMO 09:17 MTTR
CMO?
CMO?
Church & Dwight price target raised to $120 from $100 at Truist 09:17 CHD Truist analyst Bill Chappell raised the firm's price target on Church & Dwight to $120 from $100 and keeps a Buy rating on the shares after its Q4 results and FY22 guidance. The analyst states the setup for 2022 looks "highly achievable" for Church & Dwight, and while its gross margins will be down on increased costs, this looks fairly minor relative to what many of the company's CPG peers have highlighted.
XpresSpa extends airport-based biosurveillance program with CDC 09:08 XSPA
Stratasys demand checks 'well above expectations,' says Lake Street 08:58 SSYS Lake Street analyst Troy…
Nano Dimension reports preliminary Q4 revenue $7M, up 255% over 4Q20 08:46 NNDM Nano Dimension announced a preview of its financial results for the fourth quarter ended December 31st, 2021 and full year ended December 31, 2021. On a preliminary basis, Nano Dimension reported unaudited approximated consolidated revenues of $7 million for the fourth quarter ended December 31, 2021, and $10 million for the full year ended December 31, 2021. Unaudited consolidated cash and deposits balances as of the same date were approximately $1,355,000,000.
XpresSpa extends airport-based biosurveillance program with CDC 09:08 XSPA
Stratasys demand checks 'well above expectations,' says Lake Street 08:58 SSYS Lake Street analyst Troy…
Nano Dimension reports preliminary Q4 revenue $7M, up 255% over 4Q20 08:46 NNDM Nano Dimension announced a preview of its financial results for the fourth quarter ended December 31st, 2021 and full year ended December 31, 2021. On a preliminary basis, Nano Dimension reported unaudited approximated consolidated revenues of $7 million for the fourth quarter ended December 31, 2021, and $10 million for the full year ended December 31, 2021. Unaudited consolidated cash and deposits balances as of the same date were approximately $1,355,000,000.
My Spidy sense has been around this name..something is cooking.
Gamida Cell to begin rolling BLA submission for omidubicel 08:40 GMDA We are pleased that productive interactions with the FDA enable us to initiate a rolling submission of the BLA for omidubicel this quarter and to complete the full BLA submission during the first half of this year," said Julian Adams, Ph.D., Chief Executive Officer of Gamida Cell. "As we advance omidubicel towards potential approval, we will be assessing strategic alternatives for the best way to bring this important therapy to patients, including potential U.S. or global commercialization partnerships. With the strategic steps we are taking, we believe Gamida Cell will be in a stronger position to support omidubicel through the regulatory approval process while we also continue to advance our NK cell pipeline programs, all as intended to serve our goal of providing access to life-saving cell therapies to patients in need." Gamida Cell ended 2021 with approximately $96.1M in cash and cash equivalents. The company expects cash used for ongoing operating activities in 2022 to range from $60M to $70M in cash and cash equivalents based on its current operating plans. The company anticipates that its current cash will support the company's ongoing operating activities into mid-2023, excluding any additional financing or business development activities that may be undertaken. Gamida Cell plans to report its fourth quarter and full-year 2021 financial results on March 16, 2022, at which time the company will provide an update on its 2022 milestones and more detailed financial guidance.
Gamida Cell to begin rolling BLA submission for omidubicel 08:40 GMDA We are pleased that productive interactions with the FDA enable us to initiate a rolling submission of the BLA for omidubicel this quarter and to complete the full BLA submission during the first half of this year," said Julian Adams, Ph.D., Chief Executive Officer of Gamida Cell. "As we advance omidubicel towards potential approval, we will be assessing strategic alternatives for the best way to bring this important therapy to patients, including potential U.S. or global commercialization partnerships. With the strategic steps we are taking, we believe Gamida Cell will be in a stronger position to support omidubicel through the regulatory approval process while we also continue to advance our NK cell pipeline programs, all as intended to serve our goal of providing access to life-saving cell therapies to patients in need." Gamida Cell ended 2021 with approximately $96.1M in cash and cash equivalents. The company expects cash used for ongoing operating activities in 2022 to range from $60M to $70M in cash and cash equivalents based on its current operating plans. The company anticipates that its current cash will support the company's ongoing operating activities into mid-2023, excluding any additional financing or business development activities that may be undertaken. Gamida Cell plans to report its fourth quarter and full-year 2021 financial results on March 16, 2022, at which time the company will provide an update on its 2022 milestones and more detailed financial guidance.
I chose them because I read their quarterly early this morning. But yes, since it has been in and out of the Garden, I thought I'd point it out.
I know you chose this particular airline because I used to be long. That was a ways ago- we made a bundle.
On a lighter note... Have you by any chance caught the latest episode of "Ancient Aliens"?
The guy with the funny hair, Georgios something (greek name)... pretty much confirms we're not alone.